-
4组年龄、孕前体质量、孕周、产妇类型差异均无统计学意义(P>0.05),SBP与DBP水平4组间均为伴严重表现子痫前期组>不伴严重表现子痫前期组>HDCP组>对照组(P < 0.05~P < 0.01)(见表 1)。
分组 n 年龄/岁 孕前体质量/kg 孕周/周 初产妇 经产妇 SBP/(mmol/L) DBP/(mmol/L) 对照组 68 26.89±3.43 54.32±5.64 38.08±0.93 43 25 136.53±7.51 87.29±6.84 HDCP组 25 27.28±3.16 54.57±5.28 38.21±0.79 16 9 142.21±8.04** 92.04±7.02** 不伴严重表现子痫前期组 34 27.47±2.86 54.76±5.92 38.42±0.91 23 11 147.05±8.63**△ 95.89±7.26**△ 伴严重表现子痫前期组 21 27.12±3.05 55.04±4.73 37.96±0.82 15 6 153.47±9.62**△△## 100.84±8.29**△△# F — 0.27 0.11 1.53 0.58□ 28.14 23.67 P — >0.05 >0.05 >0.05 >0.05 < 0.01 < 0.01 MS组内 — 10.305 30.586 0.790 — 66.936 51.606 □示χ2值。q检验:与对照组比较** P < 0.01;与HDCP组比较△P < 0.05,△△P0.01;与不伴严重表现子痫前期组比较#P < 0.05,##P < 0.01 表 1 4组一般资料比较(x±s)
-
4组血清CHE表达为伴严重表现子痫前期组 < 不伴严重表现子痫前期组和HDCP组 < 对照组(P < 0.01);GGT与LDH表达为伴严重表现子痫前期组>不伴严重表现子痫前期组>HDCP组>对照组(P < 0.05~P < 0.01)(见表 2)。
分组 n CHE/(kU/L) GGT/(U/L) LDH/(IU/L) 对照组 68 4.57±1.36 17.83±6.76 131.62±25.83 HDCP组 25 3.49±1.02** 24.52±9.24** 198.02±32.96** 不伴严重表现子痫前期组 34 3.15±0.83** 29.97±10.74**△ 235.94±36.58**△△ 伴严重表现子痫前期组 21 2.08±0.69**△△## 41.06±13.35**△△## 314.50±68.23**△△## F — 31.26 37.52 145.25 P — <0.01 <0.01 <0.01 MS组内 — 1.258 86.679 1 444.710 q检验:与对照组比较** P < 0.01;与HDCP组比较△P < 0.05,△△P < 0.01;与不伴严重表现子痫前期组比较##P < 0.01 表 2 4组血清CHE、GGT、LDH表达比较(x±s)
-
HDCP病人血清CHE表达与SBP、DBP水平均呈负相关关系(P < 0.01),GGT、LDH表达与SBP、DBP水平均呈正相关关系(P < 0.01)(见表 3)。
项目 CHE GGT LDH SBP -0.595** 0.618** 0.729** DBP -0.583** 0.604** 0.697** **P < 0.01 表 3 HDCP病人血清各指标与血压水平的关系(r)
-
在控制年龄、孕前体质量、孕周、产妇类型等基线资料后,经logistic回归分析发现,血清CHE水平与子痫前期发病呈负相关关系(P < 0.01),GGT、LDH与子痫前期发病均呈正相关关系(P < 0.01)(见表 4)。
变量 B SE Waldχ2 P OR 95%CI CHE -0.954 0.324 8.663 <0.01 0.385 0.226~0.657 GGT 1.723 0.547 9.921 <0.01 5.601 3.562~8.806 LDH 1.555 0.468 11.047 <0.01 4.737 2.475~9.068 表 4 血清各指标与子痫前期发病关系的logistic回归分析
-
随访至分娩,无脱落病例。出现不良妊娠结局HDCP病人血清CHE表达明显低于未出现不良妊娠结局HDCP病人(P < 0.01),GGT、LDH表达均明显高于未出现不良妊娠结局HDCP病人(P < 0.01)(见表 5)。
分组 n CHE/(kU/L) GGT/(U/L) LDH/(IU/L) 出现不良妊娠结局 31 2.56±0.75 37.58±12.06 283.04±46.52 未出现不良妊娠结局 49 3.25±1.04 27.13±10.49 220.46±39.07 t — 3.20 4.10 6.48 P — < 0.01 < 0.01 < 0.01 表 5 是否出现不良妊娠结局HDCP病人血清各指标表达比较(x±s)
-
血清CHE、GGT、LDH预测HDCP病人出现不良妊娠结局的最佳截断值分别≤2.83 kU/L、>32.16 U/L、>256.06 IU/L,其曲线下面积(AUC)均小于联合预测(P < 0.01)(见表 6、图 1)。
指标 AUC 95%CI P 截断值 敏感度/% 特异度/% CHE 0.766 0.658~0.854 <0.01 ≤2.83 kU/L 74.19 69.39 GGT 0.801 0.697~0.882 <0.01 >32.16 U/L 70.97 77.55 LDH 0.798 0.693~0.879 <0.01 >256.06 IU/L 70.97 79.59 各指标联合 0.891 0.801~0.949 0.01 — 83.87 85.71 表 6 血清各指标预测HDCP病人出现不良妊娠结局的ROC曲线分析
妊娠期高血压疾病病人血CHE、GGT、LDH与病情程度的相关性研究
Study on the correlation between the levels of CHE, GGT and LDH, and severity of hypertensive disorder complicating pregnancy patients
-
摘要:
目的探讨妊娠期高血压疾病(HDCP)病人血清胆碱酯酶(CHE)、γ-谷氨酰转肽酶(GGT)、乳酸脱氢酶(LDH)表达变化及与病情程度的相关性。 方法选取80例HDCP病人,依据HDCP进展情况分为伴严重表现子痫前期组21例、不伴严重表现子痫前期组34例、单纯HDCP组25例,另选同期68名正常妊娠孕妇为对照组。比较4组血清CHE、GGT、LDH表达,分析HDCP病人血清各指标表达与血压指标[收缩压(SBP)、舒张压(DBP)]关系及与病人子痫前期发生的关联性,探讨血清各指标预测HDCP病人出现不良妊娠结局的价值。 结果SBP、DBP水平为伴严重表现子痫前期组>不伴严重表现子痫前期组>HDCP组>对照组(P < 0.05~P < 0.01);血清CHE为伴严重表现子痫前期组<不伴严重表现子痫前期组<HDCP组<对照组(P < 0.01);血清GGT、LDH为伴严重表现子痫前期组>不伴严重表现子痫前期组>HDCP组>对照组(P < 0.05~P < 0.01);HDCP病人血清CHE表达与SBP、DBP水平均呈负相关关系(P < 0.01),GGT、LDH表达与SBP、DBP水平均呈正相关关系(P < 0.01)。在控制年龄、孕前体质量、孕周、产妇类型后,血清CHE水平与子痫前期发病呈负相关关系(P < 0.01),GGT、LDH与子痫前期发病均呈正相关关系(P < 0.01)。随访至分娩,出现不良妊娠结局HDCP病人血清CHE表达低于未出现不良妊娠结局HDCP病人(P < 0.01),GGT、LDH表达高于未出现不良妊娠结局HDCP病人(P < 0.01)。血清CHE、GGT、LDH预测HDCP病人出现不良妊娠结局的最佳截断值分别≤ 2.83 kU/L、>32.16 U/L、>256.06 IU/L,其曲线下面积均小于联合预测。 结论血清CHE、GGT、LDH异常表达是子痫前期发生的重要影响因素,并与HDCP病人病情程度存在一定相关性,三者联合预测HDCP病人出现不良妊娠结局效果更好。 Abstract:ObjectiveTo investigate the changes of serum levels of cholinesterase(CHE), γ-glutamyl transpeptidase(GGT) and lactate dehydrogenase(LDH) expression in patients with hypertensive disorder complicating pregnangcy(HDCP), and their correlation with the degree of disease. MethodsEighty patients with HDCP were selected, and divided into the severe preeclampsia group(21 cases), non-severe preeclampsia group(34 cases) and simple HDCP group(25 cases) according to the progress of HDCP, and 68 normal pregnant women in the same period were selected as the control group.The serum levels of CHE, GGT and LDH in four groups were measured and compared.The relationship between the serum indicators, and levels of SBP and DBP, occurrence of preeclampsia in HDCP patients were analyzed, and the value of serum indexes in predicting adverse pregnancy outcome in HDCP patients was investigated. ResultsThe levels of SBP and DBP in the severe preeclampsia group, non-severe preeclampsia group, HDCP group and control group gradually decreased in turn(P < 0.05 to P < 0.01).The levels of CHE in the severe preeclampsia group, non-severe preeclampsia group, HDCP group and control group gradually increased in turn(P < 0.05 to P < 0.01).The levels of GGT and LDH in severe preeclampsia group, non-severe preeclampsia group, HDCP group and control group gradually decreased in turn(P < 0.05 to P < 0.01).The serum levels of CHE in HDCP patients was negatively correlated with the levels of SBP and DBP(P < 0.01), and the serum levels of GGT and LDH were positively correlated with the levels of SBP and DBP(P < 0.01).After controlling the age, prepregnancy body weight, gestational age and maternal type, the serum level of CHE was negatively correlated with the onset of preeclampsia(P < 0.01), and the levels of GGT and LDH were positively correlated with the onset of preeclampsia(P < 0.01).During follow-up to delivery, the expression of CHE in HDCP patients with adverse pregnancy outcome was lower than that in HDCP patients without adverse pregnancy outcome(P < 0.01), while the expression of GGT and LDH in HDCP patients with adverse pregnancy outcome were higher than that in HDCP patients without adverse pregnancy outcome(P < 0.01).The best cutoff values of CHE, GGT and LDH in predicting adverse pregnancy outcomes in HDCP patients were ≤ 2.83 kU/L, >32.16 U/L and>256.06 IU/L, respectively, and the areas under the curve were smaller than that in combined prediction. ConclusionsThe abnormal expression of serum CHE, GGT and LDH is an important influencing factor for the occurrence of preeclampsia, has a certain correlation with the degree of illness in HDCP patients, and the combination of the three is better in predicting adverse pregnancy outcomes in patients with HDCP. -
表 1 4组一般资料比较(x±s)
分组 n 年龄/岁 孕前体质量/kg 孕周/周 初产妇 经产妇 SBP/(mmol/L) DBP/(mmol/L) 对照组 68 26.89±3.43 54.32±5.64 38.08±0.93 43 25 136.53±7.51 87.29±6.84 HDCP组 25 27.28±3.16 54.57±5.28 38.21±0.79 16 9 142.21±8.04** 92.04±7.02** 不伴严重表现子痫前期组 34 27.47±2.86 54.76±5.92 38.42±0.91 23 11 147.05±8.63**△ 95.89±7.26**△ 伴严重表现子痫前期组 21 27.12±3.05 55.04±4.73 37.96±0.82 15 6 153.47±9.62**△△## 100.84±8.29**△△# F — 0.27 0.11 1.53 0.58□ 28.14 23.67 P — >0.05 >0.05 >0.05 >0.05 < 0.01 < 0.01 MS组内 — 10.305 30.586 0.790 — 66.936 51.606 □示χ2值。q检验:与对照组比较** P < 0.01;与HDCP组比较△P < 0.05,△△P0.01;与不伴严重表现子痫前期组比较#P < 0.05,##P < 0.01 表 2 4组血清CHE、GGT、LDH表达比较(x±s)
分组 n CHE/(kU/L) GGT/(U/L) LDH/(IU/L) 对照组 68 4.57±1.36 17.83±6.76 131.62±25.83 HDCP组 25 3.49±1.02** 24.52±9.24** 198.02±32.96** 不伴严重表现子痫前期组 34 3.15±0.83** 29.97±10.74**△ 235.94±36.58**△△ 伴严重表现子痫前期组 21 2.08±0.69**△△## 41.06±13.35**△△## 314.50±68.23**△△## F — 31.26 37.52 145.25 P — <0.01 <0.01 <0.01 MS组内 — 1.258 86.679 1 444.710 q检验:与对照组比较** P < 0.01;与HDCP组比较△P < 0.05,△△P < 0.01;与不伴严重表现子痫前期组比较##P < 0.01 表 3 HDCP病人血清各指标与血压水平的关系(r)
项目 CHE GGT LDH SBP -0.595** 0.618** 0.729** DBP -0.583** 0.604** 0.697** **P < 0.01 表 4 血清各指标与子痫前期发病关系的logistic回归分析
变量 B SE Waldχ2 P OR 95%CI CHE -0.954 0.324 8.663 <0.01 0.385 0.226~0.657 GGT 1.723 0.547 9.921 <0.01 5.601 3.562~8.806 LDH 1.555 0.468 11.047 <0.01 4.737 2.475~9.068 表 5 是否出现不良妊娠结局HDCP病人血清各指标表达比较(x±s)
分组 n CHE/(kU/L) GGT/(U/L) LDH/(IU/L) 出现不良妊娠结局 31 2.56±0.75 37.58±12.06 283.04±46.52 未出现不良妊娠结局 49 3.25±1.04 27.13±10.49 220.46±39.07 t — 3.20 4.10 6.48 P — < 0.01 < 0.01 < 0.01 表 6 血清各指标预测HDCP病人出现不良妊娠结局的ROC曲线分析
指标 AUC 95%CI P 截断值 敏感度/% 特异度/% CHE 0.766 0.658~0.854 <0.01 ≤2.83 kU/L 74.19 69.39 GGT 0.801 0.697~0.882 <0.01 >32.16 U/L 70.97 77.55 LDH 0.798 0.693~0.879 <0.01 >256.06 IU/L 70.97 79.59 各指标联合 0.891 0.801~0.949 0.01 — 83.87 85.71 -
[1] 胡蓉, 李笑天. 妊娠期高血压疾病降压的再认知及管理与子痫前期防范[J]. 中国实用妇科与产科杂志, 2018, 34(5): 24. [2] 许琦, 张颜秋, 王雁, 等. 妊娠中期胎盘生长因子水平与妊娠期高血压疾病风险的研究[J]. 中国妇产科临床杂志, 2019, 20(1): 34. [3] WANG W, FAM D, WANG J, et al. Association between hypertensive disorders complicating pregnancy and risk of placenta accreta: a meta-analysis and systematic review[J]. Hypert Pregn, 2018, 37(3): 168. doi: 10.1080/10641955.2018.1498880 [4] 王勇, 李发红, 韩娜, 等. 胎盘蛋白13促进妊娠期高血压疾病患者血管损伤修复的作用及机制研究[J]. 现代妇产科进展, 2018, 27(8): 589. [5] 聂星, 黄道超, 钟海英, 等. 肌肽对小鼠化学性肝损伤氧化应激和炎症因子的影响[J]. 免疫学杂志, 2018, 34(12): 1059. [6] 王桃桃. 胎盘中内脂素、网膜素表达与妊娠期高血压疾病相关性研究[D]. 昆明: 昆明医科大学, 2017. [7] 杨孜, 张为远. 妊娠期高血压疾病诊治指南(2020)[J]. 中华妇产科杂志, 2020, 55(4): 277. [8] 罗晓蕾, 王涛. 2019年ACOG妊娠期高血压疾病妇产科医师临床管理指南要点解读[J]. 实用妇产科杂志, 2019, 35(4): 259. [9] 刘怀昌, 肖磊, 徐智立, 等. 妊娠期高血压疾病对孕妇动脉弹性和血管内皮功能的影响[J]. 中华高血压杂志, 2019, 27(4): 372. [10] DAVE A, MARU L, JAIN A. LDH (Lactate dehydrogenase): a biochemical marker for the prediction of adverse outcomes in pre-eclampsia and eclampsia[J]. J Obstet Gynaecol India, 2016, 66(1): 23. doi: 10.1007/s13224-014-0645-x [11] KASRAEIAN M, ASADI N, VAFAEI H, et al. Evaluation of serum biomarkers for detection of preeclampsia severity in pregnant women[J]. Pak J Med Sci, 2018, 34(4): 869. [12] 陈大立, 柴利强, 彭兰, 等. 血清乳酸脱氢酶与子痫前期及妊娠不良结局的关系[J]. 国际妇产科学杂志, 2016, 43(4): 393. [13] BURWICK RM, MONICA R, BEERAKA SS, et al. Evaluation of hemolysis as a severe feature of preeclampsia[J]. Hypertension, 2018, 72(2): 460. doi: 10.1161/HYPERTENSIONAHA.118.11211 [14] 蒋利红, 施晓飞. 妊娠期高血压疾病孕妇的血清LDH水平及其对PE的预测价值[J]. 中国妇幼健康研究, 2018, 29(9): 1119. doi: 10.3969/j.issn.1673-5293.2018.09.013 [15] TRAN TT, AHN J, REAU NS. ACG clinical guideline: liver disease and pregnancy[J]. Am J Gastroenterol, 2016, 111(2): 176. doi: 10.1038/ajg.2015.430 [16] GRANGER JP, SPRADLEY FT, BAKRANIA BA. The endothelin system: a critical player in the pathophysiology of preeclampsia[J]. Curr Hypertens Rep, 2018, 20(4): 32. doi: 10.1007/s11906-018-0828-4 [17] 杨丽惠, 蒋晓红, 王龙, 等. 血清尿酸水平对新诊断2型糖尿病患者肌电图的影响[J]. 中国糖尿病杂志, 2017, 25(2): 103. [18] 舒琴, 李雨真, 张贵敏. 高血压患者血清γ-谷氨酰转移酶水平与冠状动脉病变程度的关系[J]. 中国心血管病研究, 2018, 16(11): 1000. doi: 10.3969/j.issn.1672-5301.2018.11.009 [19] DACAJ R, IZETBEGOVIC S, STOJKANOVIC G, et al. Elevated liver enzymes in cases of preeclampsia and intrauterine growth restriction[J]. Med Arch, 2016, 70(1): 44. doi: 10.5455/medarh.2016.70.44-47 [20] GOULOPOULOU S. Vascularendothelium: a potential source of podocalyxin in serum from pregnancies with preeclampsia[J]. J Hypertens, 2017, 35(11): 2176. doi: 10.1097/HJH.0000000000001468 [21] SEPČIĆK, SABOTIČ J, A OHM R, et al. First evidence of cholinesterase-like activity in Basidiomycota[J]. PLoS One, 2019, 14(4): e0216077. [22] 应萍, 吴朝勇, 夏桂玉. 重度子痫前期孕妇血清前白蛋白胆碱酯酶分析[J]. 浙江临床医学, 2016, 18(11): 2108.